Sorafenib N-Oxide structure
|
Common Name | Sorafenib N-Oxide | ||
---|---|---|---|---|
CAS Number | 583840-03-3 | Molecular Weight | 483.84300 | |
Density | 1.455g/cm3 | Boiling Point | 591.655ºC at 760 mmHg | |
Molecular Formula | C21H13ClD3F3N4O4 | Melting Point | 220-222ºC | |
MSDS | N/A | Flash Point | 311.622ºC |
Use of Sorafenib N-OxideSorafenib N-oxide is an active metabolite of sorafenib (BAY 43-9006), an inhibitor of Raf-1, B-RAF, and receptor tyrosine kinases. Sorafenib N-oxide inhibits FLT3 that contains the internal tandem duplication mutation (FLT3-ITD) and inhibits proliferation of MV4-11 acute myeloid leukemia (AML) cells expressing FLT3-ITD. It is selective for AML cell lines containing FLT3-ITD over lines containing wild-type FLT3. Sorafenib N-oxide is also a linear-mixed inhibitor of the cytochrome P450 (CYP) isoform CYP3A4. |
Name | Sorafenib N-Oxide |
---|---|
Synonym | More Synonyms |
Density | 1.455g/cm3 |
---|---|
Boiling Point | 591.655ºC at 760 mmHg |
Melting Point | 220-222ºC |
Molecular Formula | C21H13ClD3F3N4O4 |
Molecular Weight | 483.84300 |
Flash Point | 311.622ºC |
Exact Mass | 483.10000 |
PSA | 104.92000 |
LogP | 6.12010 |
Index of Refraction | 1.601 |
~55% Sorafenib N-Oxide CAS#:583840-03-3 |
Literature: BAYER CORPORATION Patent: US2003/216446 A1, 2003 ; US 20030216446 A1 |
Precursor 1 | |
---|---|
DownStream 0 |
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-1-oxidopyridin-1-ium-2-carboxamide |